Raymond James analyst Andrew Cooper downgraded Exact Sciences (EXAS) to Market Perform from Outperform without a price target. The stock has run more than 125% from October lows, largely on step function moves following the ECLIPSE readout from Guardant Health (GH) and a positive Q4 pre-announcement, Cooper tells investors in a research note. While the analyst says Cologuard remains in the lead on overall sensitivity and advanced adenoma detection for noninvasive CRC screening, CMS coverage is likely to persist unanswered for some time.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on EXAS:
- Exact Sciences downgraded to Market Perform from Outperform at Raymond James
- EXACT Sciences call volume above normal and directionally bullish
- Exact Sciences price target raised to $44 from $35 at Craig-Hallum
- Exact reports preliminary Q4 revenue $550.7M-$552.7M, consensus $506.48M
- Exact Sciences Announces Preliminary Fourth Quarter 2022 Results
